Amphastar Pharmaceuticals (AMPH) Invested Capital (2013 - 2026)

Amphastar Pharmaceuticals' Invested Capital history runs 14 years deep, the most recent figure standing at $773.4 million for Q1 2026.

• In Q1 2026, Invested Capital changed 0.27% year-over-year to $773.4 million; the TTM figure through Mar 2026 stood at $773.4 million (changed 0.27% YoY), while the FY2025 annual figure was $1.0 billion, up 41.84% from the prior year.
• Invested Capital was $773.4 million for Q1 2026 at Amphastar Pharmaceuticals, down from $1.0 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $1.1 billion in Q2 2023 to a low of $505.2 million in Q3 2022.
• Historically, Invested Capital has averaged $725.3 million across 5 years, with a median of $727.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Invested Capital surged 91.77% in 2023, then plunged 34.49% in 2024.
• A 5-year view of Invested Capital shows it stood at $596.9 million in 2022, then gained by 7.15% to $639.6 million in 2023, then grew by 14.51% to $732.4 million in 2024, then surged by 41.84% to $1.0 billion in 2025, then retreated by 25.54% to $773.4 million in 2026.
• The last three Invested Capital figures came in at $773.4 million (Q1 2026), $1.0 billion (Q4 2025), and $801.1 million (Q3 2025), per Business Quant data.